TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00700375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate
Description: 8.4%sodium bicarbonate 0.5ml/kg bolus injection before procedure and hydration with 154mEq/l sodium bicarbonate 1ml/kg/Hr for 6 hours after the procedure

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Chloride
Description: 8.4%sodium bicarbonate 0.5ml/kg bolus injection before procedure and hydration with 154mEq/l sodium bicarbonate 1ml/kg/Hr for 6 hours after the procedure
Study: NCT04571047

Intervention type: OTHER
Intervention: Time to treatment
Description: Treatment before or after 4 weeks after diagnosis
Study: NCT02408042

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ifosfamide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ifosfamide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mesna

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mesna

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brentuximab vedotin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Study: NCT02907242

Intervention type: OTHER
Group type: OTHER
Intervention: Revealment
Description: Cerebroplacental ratio revealment
Study: NCT05237115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clostridium butyricum capsule
Description: Clostridium butyricum group: given for 14 days at a dose of Clostridium butyricum capsule 420mg 3 capsules BID, esomeprazole 40 mg BID, amoxicillin 500 mg 2 capsules BID, and clarithromycin 500 mg 1 tablet BID.
Study: NCT01593787

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCZ696
Description: 100 mg, 200 mg, 400 mg tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCZ696
Description: 100 mg, 200 mg, 400 mg tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCZ696
Description: 100 mg, 200 mg, 400 mg tablets.
Study: NCT05237115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: esomeprazole
Description: Esmeprazole 40mg 1tablet BID plus amoxicillin 500 mg 2 capsules BID, clarithromycin 500 mg 1 tablet BID, and colloidal bismuth tartrate capsule 55 mg 4 capsules BID or Bacillus coagulans tablets 350mg 3 capsules BID and Clostridium butyricum capsule 420mg 3 capsules BID as a dose given for bismuth-containing quadruple therapy or probiotics combined with triple therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: esomeprazole
Description: Esmeprazole 40mg 1tablet BID plus amoxicillin 500 mg 2 capsules BID, clarithromycin 500 mg 1 tablet BID, and colloidal bismuth tartrate capsule 55 mg 4 capsules BID or Bacillus coagulans tablets 350mg 3 capsules BID and Clostridium butyricum capsule 420mg 3 capsules BID as a dose given for bismuth-containing quadruple therapy or probiotics combined with triple therapy.
Study: NCT04287699

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: labor dance
Description: The pregnant women and their spouses/partners who wanted to perform the practice were asked to inform the researcher when the labor started. The researcher stayed with the pregnant women and their spouses during the practice and labor process. The pregnant women started to dance with their spouses during the active phase of the labor process accompanied by meditation music in a dim, silent environment. The spouse or partner massaged the pregnant woman's sacral area while dancing.
Study: NCT02056990

Intervention type: OTHER
Intervention: Advice
Study: NCT04188873

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Preparation Varenicline and Standard Duration Varenicline
Description: 16 weeks of varenicline starting 4 weeks pre-quit

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Preparation Varenicline and Standard Duration Varenicline
Description: 16 weeks of varenicline starting 4 weeks pre-quit
Study: NCT04361799

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CamAPS
Description: Fully automated closed-loop subcutaneous insulin delivery system. A model predictive controller modulates insulin delivery every 10-12 minutes based on interstitial glucose measurements.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard insulin therapy
Description: Standard insulin therapy according to local clinical practice.
Study: NCT01852123

Intervention type: DEVICE
Group type: OTHER
Intervention: High-sensitivity troponin I assay

Intervention type: DEVICE
Group type: OTHER
Intervention: High-sensitivity troponin I assay
Study: NCT00001322

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide Acetate 3.75
Description: Eight to 12 weeks of GnRH agonist, Leuprolide Acetate 3.75 mg given intramuscularly monthly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide Acetate 3.75
Description: Eight to 12 weeks of GnRH agonist, Leuprolide Acetate 3.75 mg given intramuscularly monthly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide Acetate 3.75
Description: Eight to 12 weeks of GnRH agonist, Leuprolide Acetate 3.75 mg given intramuscularly monthly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol
Description: Transdermal Estradiol, 100mcg/day by skin patch

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol
Description: Transdermal Estradiol, 100mcg/day by skin patch

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: Progesterone suppository, 200mg vaginally twice/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: Progesterone suppository, 200mg vaginally twice/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo suppository
Description: Placebo suppository twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo suppository
Description: Placebo suppository twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo patch
Description: Placebo by skin patch

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo patch
Description: Placebo by skin patch
Study: NCT02027233

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nasopharyngeal sample
Description: The nasopharyngeal sample will be used to find the types and subtypes of influenza virus and other respiratory viruses (VRS, SARS-CoV-2 and others).
Study: NCT03662126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KRT-232
Description: KRT-232, administered by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KRT-232
Description: KRT-232, administered by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KRT-232
Description: KRT-232, administered by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KRT-232
Description: KRT-232, administered by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KRT-232
Description: KRT-232, administered by mouth

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Best Available Therapy (BAT)
Description: Best available therapy options include:~1. hydroxyurea~2. chemotherapy or~3. supportive care (including but not limited to corticosteroids and androgens; JAK inhibitors not allowed).
Study: NCT01999985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib - 1A
Description: 1A: Begins Day 8. Level 1 - 100 mg, Level 2 - 100 mg, Level 3 - 140 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib - 1A
Description: 1A: Begins Day 1. Level 1 - 30 mg, Level 2 - 40 mg, Level 3 - 40 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib - 1B
Description: In Phase 1B, a mutationally selected 20 participants (total) will be treated at the recommended dose to confirm tolerability and evaluate for early response signal.
Study: NCT04188873

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Preparation Varenicline and Extended Duration Varenicline
Description: 28 weeks of varenicline starting 4 weeks pre-quit
Study: NCT01999985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib - 1B
Description: In Phase 1B, a mutationally selected 20 participants (total) will be treated at the recommended dose to confirm tolerability and evaluate for early response signal.
Study: NCT03403907

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: twice a day for 4 months (Streptococcus thermophilus, Lactobacillus acidophilus, L.plantarum, L. paracasei, L. delbrueckii subs bulgaricus, Bifidobacterium breve, B.longus y B.infantis. y CD2).
Study: NCT01693679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telbivudine, Lamivudine, Adefovir ,Enecavir
Description: investigational Telbivudine,600mg,daily,oral.comparator Lamivudine,100mg daily, oral,Adefovir,10mg,daily,oral,Enecavir,0.5mg,daily,oral.
Study: NCT02121795

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FTC/TDF
Description: 200/300 mg FDC tablets administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F/TAF
Description: Tablets administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allowed third antiretroviral agent
Description: An allowed third antiretroviral agent of the participant's pre-existing regimen may include one of the following: ritonavir-boosted atazanavir (ATV/r), ritonavir-boosted lopinavir (LPV/r), ritonavir-boosted darunavir (DRV/r), efavirenz (EFV; Sustiva®), rilpivirine (RPV; Edurant®), nevirapine (NVP;Viramune®), raltegravir (RAL; Isentress®), dolutegravir (DTG;Tivicay®), and maraviroc (MVC; Selzentry®).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allowed third antiretroviral agent
Description: An allowed third antiretroviral agent of the participant's pre-existing regimen may include one of the following: ritonavir-boosted atazanavir (ATV/r), ritonavir-boosted lopinavir (LPV/r), ritonavir-boosted darunavir (DRV/r), efavirenz (EFV; Sustiva®), rilpivirine (RPV; Edurant®), nevirapine (NVP;Viramune®), raltegravir (RAL; Isentress®), dolutegravir (DTG;Tivicay®), and maraviroc (MVC; Selzentry®).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTC/TDF Placebo
Description: Tablets administered orally once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: F/TAF Placebo
Description: Tablets administered orally once daily
Study: NCT01704755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-450/r/ABT-267, ABT-333
Description: Tablet; ABT-450 coformulated with ritonavir and ABT-267; ABT-333 tablet
Study: NCT04188873

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Preparation Varenicline and Extended Duration Varenicline
Description: 28 weeks of varenicline starting 4 weeks pre-quit

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Duration Varenicline
Description: 12 weeks of varenicline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Duration Varenicline
Description: 12 weeks of varenicline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Extended Duration Varenicline
Description: 24 weeks of varenicline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Extended Duration Varenicline
Description: 24 weeks of varenicline
Study: NCT01704755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-450/r/ABT-267, ABT-333
Description: Tablet; ABT-450 coformulated with ritonavir and ABT-267; ABT-333 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV)
Description: Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV)
Description: Capsule
Study: NCT04421040

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biotronik Biomonitor 3 implant of device
Description: The Biotronik Biomonitor 3 device will be implanted by the research team physician.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biotronik Biomonitor 3 explant of device
Description: The Biotronik Biomonitor 3 device will be removed from the patient by the research team physician.
Study: NCT01725633

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Progressive Stretching Group
Description: Participants assigned to the progressive stretching group will be provided with a progressive stretching program that matches the aerobic training interventions in terms of program length (16 weeks), social interaction (all sessions will be supervised), and session duration (20-45 minutes/session, ± 10 minutes).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nonlinear Aerobic Training
Description: Participants assigned to the nonlinear aerobic training arm will perform no more than 150 minutes per week of structured supervised aerobic training as part of clinical trial participation. Exercise performed outside the structured sessions (i.e., contamination) will be assessed via self-report of exercise behavior using the Godin-Leisure Time Exercise Questionnaire (GLTEQ). For ethical reasons, we will not instruct participants not to exercise outside the structured sessions, but we we will encourage participants to maintain their level of exercise behavior prior to study initiation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood draw
Description: At Weeks 4, and 8, all participants will have a complete blood count (CBC) test performed.

Intervention type: OTHER
Group type: OTHER
Intervention: Blood draw
Description: At Weeks 4, and 8, all participants will have a complete blood count (CBC) test performed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary Exercise Testing (CPET)
Description: At the end of Week 6, participants repeat the CPET in the nonlinear aerobic training group.
Study: NCT01705977

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo plus standard therapy
Description: Placebo plus standard therapy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Belimumab 10 mg/kg plus standard therapy
Description: Belimumab 10 mg/kg plus standard therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard therapy
Description: Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressives; other biologics are not permitted.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard therapy
Description: Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressives; other biologics are not permitted.
Study: NCT00742794

Intervention type: OTHER
Intervention: Observation
Description: Observation of sting frequency
Study: NCT03407313

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rotational fractional resection (1.5mm diameter device)
Description: Single treatment of skin resection and focal lipectomy (removal of loose skin and fat)
Study: NCT04188873

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Preparation Combination NRT and Standard Duration Combination NRT
Description: 16 weeks of nicotine patch + nicotine mini-lozenge starting 4 weeks pre-quit

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Preparation Combination NRT and Standard Duration Combination NRT
Description: 16 weeks of nicotine patch + nicotine mini-lozenge starting 4 weeks pre-quit

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Preparation Combination NRT and Extended Duration Combination NRT
Description: 28 weeks of nicotine patch + nicotine mini-lozenge starting 4 weeks pre-quit

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Preparation Combination NRT and Extended Duration Combination NRT
Description: 28 weeks of nicotine patch + nicotine mini-lozenge starting 4 weeks pre-quit

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Duration Combination NRT
Description: 12 weeks of nicotine patch + nicotine mini-lozenge

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Duration Combination NRT
Description: 12 weeks of nicotine patch + nicotine mini-lozenge

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Extended Duration Combination NRT
Description: 24 weeks of nicotine patch + nicotine mini-lozenge

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Extended Duration Combination NRT
Description: 24 weeks of nicotine patch + nicotine mini-lozenge

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intensive Counseling
Description: 4 phone or video counseling sessions

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intensive Counseling
Description: 4 phone or video counseling sessions

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intensive Counseling
Description: 4 phone or video counseling sessions

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intensive Counseling
Description: 4 phone or video counseling sessions

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intensive Counseling
Description: 4 phone or video counseling sessions

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intensive Counseling
Description: 4 phone or video counseling sessions
Study: NCT01396083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone implant and sham injections
Study: NCT01063855

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets identical in appearance to dapoxetine taken 1 to 3 hours before sexual activity prn (as needed) not to be taken more than once every 24 hours for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapoxetine
Description: 30 mg to 60 mg tablets 1 to 3 hours before sexual activity prn (as needed) not to be taken more than once every 24 hours for 12 weeks.
Study: NCT04188873

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intensive Counseling
Description: 4 phone or video counseling sessions

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intensive Counseling
Description: 4 phone or video counseling sessions
Study: NCT01063855

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDE5I (phosphodiesterase-5 inhibitor)
Description: Patients were to be using a stable regimen of a PDE5-I (i.e., sildenafil, vardenafil, or tadalafil), as reported by the patient for the treatment of erectile dysfunction (ED) for at least 3 months before screening and up to 12 weeks during treatment in the study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PDE5I (phosphodiesterase-5 inhibitor)
Description: Patients were to be using a stable regimen of a PDE5-I (i.e., sildenafil, vardenafil, or tadalafil), as reported by the patient for the treatment of erectile dysfunction (ED) for at least 3 months before screening and up to 12 weeks during treatment in the study.
Study: NCT02843464

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: reported remote ischemic preconditioning (RIPC)
Description: Three five-minute cycles of upper limb ischaemia and three five-minute pauses using a blood pressure cuff inflated to 200 mmHg.
Study: NCT03060304

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: Patients in study group will receive tamoxifen at a daily dose of 40 mg from day 3 to day 8.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: estradiol valerate
Description: Patients in control group will receive estradiol valerate at a dose of 3 mg twice per day from day 3.
Study: NCT03234036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2838232 100 mg tablet
Description: It is a white to slightly colored tablet. It will be supplied as prefilled tablets in bulk for dispensing to subjects at the site according to the treatment code.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2838232 100 mg tablet
Description: It is a white to slightly colored tablet. It will be supplied as prefilled tablets in bulk for dispensing to subjects at the site according to the treatment code.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2838232 100 mg tablet
Description: It is a white to slightly colored tablet. It will be supplied as prefilled tablets in bulk for dispensing to subjects at the site according to the treatment code.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2838232 50 mg capsule
Description: It is a pink unmarked capsule. It will be supplied as prefilled capsules in bulk for dispensing to subjects at the site according to the treatment code.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2838232 50 mg capsule
Description: It is a pink unmarked capsule. It will be supplied as prefilled capsules in bulk for dispensing to subjects at the site according to the treatment code.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir 100 mg tablets
Description: It is a white film-coated ovaloid tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir 100 mg tablets
Description: It is a white film-coated ovaloid tablets.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for GSK2838232 tablets
Description: It is a white to slightly colored tablet. The placebo tablets supplied will not be identical to GSK2838232 tablets. It will be administered by site staff via an opaque card or paper tube.
Study: NCT04188873

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Minimal Counseling
Description: 2 brief phone or video counseling sessions
Study: NCT00552695

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine tetracaine
Description: Lidocaine 70 mg/tetracaine 70 mg

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo patch identical in appearance to Synera
Study: NCT02537951

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AFI microscope
Description: measurement of AFI intensities following increasing nociceptive stimulus intensities

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: negative control 1: lidocaine/prilocaine
Description: measurement of AFI intensities following lidocaine/prilocaine cream

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: negative control 2: 8% capsaicin
Description: measurement of AFI intensities following 8% capsaicin patch
Study: NCT03600831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel plus cisplatin
Description: cisplatin 25mg/m2 on day 1 and docetaxel 25mg/m2 on day 1 weekly for 5 weeks

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: radiotherapy: 50Gy (2.0 Gy/fraction, 5 days a week)

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiotherapy
Description: radiotherapy: 50Gy (2.0 Gy/fraction, 5 days a week)